/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Chemomab Therapeutics Ltd

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$2.49 -0.0158(-1.58%) CMMB at 04 Dec 2025 04:28 PM Biotechnology
Lowest Today 2.49
Highest Today 2.63
Today’s Open 2.58
Prev. Close 2.53
52 Week High 9.84
52 Week Low 2.36
Day’s Range: Low 2.49 High 2.63
52-Week Range: Low 2.36 High 9.84
1 day return -
1 Week return -3.46
1 month return -5.28
3 month return -17.7
6 month return +88.01
1 year return +50.29
3 year return +21.84
5 year return -89.47
10 year return -

Institutional Holdings

Advisory Services Network, LLC 0.00

Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 15.57 M

PB Ratio 1.4359

PE Ratio 0.0

Enterprise Value 6.13 M

Total Assets 16.96 M

Volume 93530

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:-66827 -0.1M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-24158586 -24.2M, FY22:-27646000 -27.6M, FY21:-12555000 -12.6M, FY20:-5930000 -5.9M, FY19:27124000 27.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-33687 -0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:-26901 -0.0M

Quarterly Net worth Q3/2025:-1742000 -1.7M, Q2/2025:-2057000 -2.1M, Q1/2025:-3323000 -3.3M, Q3/2024:-3483000 -3.5M, Q2/2024:-3631000 -3.6M

Fund house & investment objective

Company Information Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Organisation Biotechnology

Employees 0

Industry Biotechnology

CEO Dr. Adi Mor George Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow